We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters. From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1-5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease. Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.
Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience / Detti, Beatrice; Franceschini, Davide; Saieva, Calogero; Di Brina, Lucia; Baki, Mohammed; Meattini, Icro; Di Cataldo, Vanessa; Pasquetti, Eleonora Monteleone; Furfaro, Ilaria; Mancuso, Anna; Simontacchi, Gabriele; Livi, Lorenzo. - In: CANCER INVESTIGATION. - ISSN 0735-7907. - STAMPA. - 32:(2015), pp. 445-450. [10.3109/07357907.2014.958233]
Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience
MEATTINI, ICRO;DI CATALDO, VANESSA;SIMONTACCHI, GABRIELE;LIVI, LORENZO
2015
Abstract
We present a single-institution experience reporting the efficacy and safety of docetaxel, administered as first-line chemotherapy, in castration-resistant prostate cancer (CRPC), focusing on patients and treatment parameters. From November 2004 to January 2012, 51 patients received chemotherapy with docetaxel. With a mean follow-up time (from the beginning of CHT) of 1.6 years (range 0.1-5.1 years), 35 patients (68.6%) died for prostate cancer and 48 patients (94.1%) showed progression of the disease. Five factors influenced overall survival: nodal status at diagnosis, neoadjuvant hormonal therapy, number of cycles of docetaxel administered, schedule of docetaxel and ECOG performance status before starting chemotherapy.File | Dimensione | Formato | |
---|---|---|---|
Detti et al 2014 Cancer Invest.pdf
Accesso chiuso
Descrizione: Paper
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
183.94 kB
Formato
Adobe PDF
|
183.94 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.